Skip to Main Content
HBS Home
  • About
  • Academic Programs
  • Alumni
  • Faculty & Research
  • Baker Library
  • Giving
  • Harvard Business Review
  • Initiatives
  • News
  • Recruit
  • Map / Directions
Faculty & Research
  • Faculty
  • Research
  • Featured Topics
  • Academic Units
  • …→
  • Harvard Business School→
  • Faculty & Research→
Publications
Publications
  • February 2015 (Revised November 2015)
  • Case
  • HBS Case Collection

Building an Integrated Biopharma Company: Crucell (A)

By: Richard G. Hamermesh, Marianne Van Der Steen and Susan S. Harmeling
  • Format:Print
  • | Language:English
  • | Pages:13
ShareBar

Abstract

By 2009, Crucell had become the largest biopharma company in the Netherlands and a symbol of national pride. The case traces the evolution of the company from a University spin-off into a fully-integrated company. Crucell's success, particularly in the vaccine space, had begun to attract the attention of much larger pharmaceutical companies. While there was much appeal to working with these companies, these relationships could also challenge Crucell's independence. This issue is highlighted by the decision whether to partner with companies that wanted ownership of 10-20% of Crucell as part of the business development deals.

Keywords

Biotechnology; Biopharmacy Company; Licensing; Licensing Agreements In Biopharmacy; Human Cell-line Technology; Vaccine; Healthcare Innovation; Global Health; Partners and Partnerships; Entrepreneurship; Growth and Development Strategy; Biotechnology Industry; Pharmaceutical Industry; Netherlands

Citation

Hamermesh, Richard G., Marianne Van Der Steen, and Susan S. Harmeling. "Building an Integrated Biopharma Company: Crucell (A)." Harvard Business School Case 815-085, February 2015. (Revised November 2015.)
  • Educators
  • Purchase

About The Author

Richard G. Hamermesh

→More Publications

Related Work

    • February 2015 (Revised November 2015)
    • Faculty Research

    Building an Integrated Biopharma Company: Crucell (B)

    By: Richard G. Hamermesh, Marianne Van Der Steen and Susan Harmeling
    • February 2015 (Revised November 2015)
    • Faculty Research

    Building an Integrated Biopharma Company: Crucell (A)

    By: Richard G. Hamermesh, Marianne Van Der Steen and Susan S. Harmeling
Related Work
  • Building an Integrated Biopharma Company: Crucell (B) By: Richard G. Hamermesh, Marianne Van Der Steen and Susan Harmeling
  • Building an Integrated Biopharma Company: Crucell (A) By: Richard G. Hamermesh, Marianne Van Der Steen and Susan S. Harmeling
ǁ
Campus Map
Harvard Business School
Soldiers Field
Boston, MA 02163
→Map & Directions
→More Contact Information
  • Make a Gift
  • Site Map
  • Jobs
  • Harvard University
  • Trademarks
  • Policies
  • Accessibility
  • Digital Accessibility
Copyright © President & Fellows of Harvard College